UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Cardiac Safety of Osimertinib: A Review of Data

Journal of clinical oncology, 2021-02, Vol.39 (4), p.328-337

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Link zum Volltext

Verfügbarkeit prüfen

Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis

Journal of cachexia, sarcopenia and muscle, 2013-06, Vol.4 (2), p.157-169

2013

Link zum Volltext

Verfügbarkeit prüfen

Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions

Quality of life research, 2022-08, Vol.31 (8), p.2535-2543

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions

Quality of life research, 2022-08, Vol.31 (8), p.2545-2545

2022

Link zum Volltext

Verfügbarkeit prüfen

Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses

European journal of immunology, 2004-02, Vol.34 (2), p.565-575

2004

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small-cell lung cancer: NeoADAURA

Future oncology (London, England), 2021-11, Vol.17 (31), p.4045-4055

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-08, Vol.122, p.100-106

2018

Link zum Volltext

Verfügbarkeit prüfen

How patients being treated for non-small cell lung cancer value treatment benefit despite side effects

Quality of life research, 2022-01, Vol.31 (1), p.135-146

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

European journal of cancer (1990), 2020-01, Vol.125, p.49-57

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

Journal of thoracic oncology, 2022-05, Vol.17 (5), p.718-723

2022

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Targeted oncology, 2021-03, Vol.16 (2), p.165-176

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1 m who have not experienced disease progression on first-line therapy

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-05-OT2-11-05

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-06-OT2-11-06

2022

Link zum Volltext

Verfügbarkeit prüfen

SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1101-TPS1101

2021

Link zum Volltext

Verfügbarkeit prüfen

Human peripheral blood mononuclear cells express GABAA receptor subunits

Molecular immunology, 2006-03, Vol.43 (9), p.1432-1442

2006

Link zum Volltext

Verfügbarkeit prüfen

Human peripheral blood mononuclear cells express GABA A receptor subunits

Molecular immunology, 2006-03, Vol.43 (9), p.1432-1442

2006

Link zum Volltext

Verfügbarkeit prüfen

Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy

The patient : patient-centered outcomes research, 2017-10, Vol.10 (5), p.593-603

2017

Link zum Volltext

Verfügbarkeit prüfen

Differential gene expression analysis in human monocyte-derived macrophages: Impact of cigarette smoke on host defence

Molecular immunology, 2010-02, Vol.47 (5), p.1058-1065

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.492-496

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.531-536

2011

Link zum Volltext

Verfügbarkeit prüfen

Human peripheral blood mononuclear cells express GABA sub(A) receptor subunits

Molecular Immunology, 2006-03, Vol.43 (9), p.1432-1442

2006

Link zum Volltext

Verfügbarkeit prüfen

Rapid simultaneous cloning of drug targets from multiple mammalian species

Alternatives to laboratory animals, 2006-06, Vol.34 (3), p.295-303

2006

Link zum Volltext

Verfügbarkeit prüfen

Living on a flammable planet: interdisciplinary, cross-scalar and varied cultural lessons, prospects and challenges

Philosophical transactions of the Royal Society of London. Series B. Biological sciences, 2016-06, Vol.371 (1696)

2016

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity of resting-state EEG features in juvenile myoclonic epilepsy and controls

Brain communications, 2022, Vol.4 (4), p.fcac180-fcac180

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Humans
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Neoplasms - Drug Therapy
(10)
Oncology
(9)
Medicine
(6)
Medicine & Public Health
(6)
Lung Cancer
(5)
Male
(5)
Mutation
(5)
Acrylamides
(4)
Aged
(4)
Aniline Compounds - Therapeutic Use
(4)
Female
(4)
Middle Aged
(4)
Original
(4)
Osimertinib
(4)
Patient Reported Outcome Measures
(4)
Protein Kinase Inhibitors - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiac Safety of Osimertinib: A Review of Data

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis

Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions

Correction to: Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions

Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small-cell lung cancer: NeoADAURA

Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer

How patients being treated for non-small cell lung cancer value treatment benefit despite side effects

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Human peripheral blood mononuclear cells express GABAA receptor subunits

Human peripheral blood mononuclear cells express GABA A receptor subunits

Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy

Differential gene expression analysis in human monocyte-derived macrophages: Impact of cigarette smoke on host defence

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists

Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists

Human peripheral blood mononuclear cells express GABA sub(A) receptor subunits

Rapid simultaneous cloning of drug targets from multiple mammalian species

Living on a flammable planet: interdisciplinary, cross-scalar and varied cultural lessons, prospects and challenges

Heterogeneity of resting-state EEG features in juvenile myoclonic epilepsy and controls

Suchergebnisse filtern